<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Economic considerations and patients&apos; preferences affect treatment selection for rheumatoid arthritis patients: A discrete choice experiment among European rheumatologists</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">;</forename><surname>Hiligsmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CAPHRI Research Institute</orgName>
								<orgName type="institution" key="instit2">Maastricht University</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Health Services Research</orgName>
								<orgName type="institution">Maastricht University</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Watson</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Leiden University Medical Center</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="laboratory">Health Economics Research Unit</orgName>
								<orgName type="institution">University of Aberdeen</orgName>
								<address>
									<settlement>Aberdeen</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Severens</forename><surname>Jl</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute for Health Policy and Management</orgName>
								<orgName type="institution">Erasmus Rotterdam University</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Fautrel</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">University</orgName>
								<address>
									<addrLine>Paris 6, GRC-UPMC08</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Pierre Louis Institute of Epidemiology and Public Health -AP-HP</orgName>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Pitie Salpetriere University Hospital</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Uhlig</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="laboratory">National Advisory Unit for Rehabilitation in Rheumatology</orgName>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Diakonhjemmet Hospital</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Van Vollenhoven</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CAPHRI Research Institute</orgName>
								<orgName type="institution" key="instit2">Maastricht University</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Maastricht University Medical Center</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Jacques</surname></persName>
							<affiliation key="aff11">
								<orgName type="laboratory">Unit for Clinical Therapy Research Inflammatory Diseases</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">University Hospital Ghent</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Detert</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Canas Da Silva</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Hospital Garcia de Orta</orgName>
								<address>
									<country>Almada Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Scirè</forename><surname>Ca</surname></persName>
							<affiliation key="aff15">
								<orgName type="laboratory">Epidemiology Unit</orgName>
								<orgName type="institution">Italian Society for Rheumatology</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Berghea</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">University of Medicine and Pharmacy Carol Davila</orgName>
								<address>
									<settlement>Bucharest</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Carmona</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Instituto de Salud Musculoesqueletica</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Péntek</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Health Economics</orgName>
								<orgName type="institution">Corvinus University of Budapest</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Flór Ferenc Hospital</orgName>
								<address>
									<settlement>Kistarcsa</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">18. Arthritis Centre</orgName>
								<orgName type="institution">Northwick Park Hospital</orgName>
								<address>
									<settlement>Harrow</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Keat</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CAPHRI Research Institute</orgName>
								<orgName type="institution" key="instit2">Maastricht University</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Maastricht University Medical Center</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<address>
									<settlement>Germany, Netherlands, Norway</settlement>
									<country>Hungary, Spain, Sweden or United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Economic considerations and patients&apos; preferences affect treatment selection for rheumatoid arthritis patients: A discrete choice experiment among European rheumatologists</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">FDCB4CAC7E06251809764DBE23388AA6</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for rheumatoid arthritis (RA) patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p><s>In a discrete choice experiment European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity.</s><s>Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental costeffectiveness ratio (ICER)).</s><s>A Bayesian efficient design defined fourteen choice sets and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries.</s></p><p><s>Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p><s>Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years).</s><s>In all countries, efficacy dominated treatment decisions followed by economic considerations and patients´ preferences.</s><s>Across countries, rheumatologists avoided selecting a treatment that patients disliked.</s><s>Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER.</s><s>Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium,</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Traditionally, drug treatment decisions for patients with rheumatoid arthritis (RA) were primarily based on benefits and risks associated with a drug.</s><s>Patient´s preferences and treatment costs usually received little attention, only <ref type="bibr" target="#b0">[1]</ref>.</s><s>The introduction of biologics has increased treatment opportunities substantially.</s><s>The new treatments are between 20 and 60 times more costly, and therefore raise concerns about affordability of RA care <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>Today, in most European countries, access to biologics is highly regulated <ref type="bibr" target="#b3">[4]</ref> .</s><s>In addition to the economic dimension becoming increasingly important, physicians across Europe are encouraged to actively involve their patients in treatment decisions.</s><s>Patient-centered-care is expected to improve adherence to agreed treatment plans and thus positively influence health outcomes <ref type="bibr" target="#b4">[5]</ref>.</s><s>However it can be a challenge to include patients´ preferences in decisions that are influenced by multiple other aspects.</s></p><p><s>Although costs and cost-effectiveness (CE) have been given consideration in recent European League Against Rheumatism (EULAR) developed treatment recommendations <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref> recommendations rely mainly on evidence for effectiveness and safety.</s><s>Optimal patient care across Europe will depend on how recommendations are implemented in the context of differences in the economic situations of countries and differences in the attitudes of physicians and patients.</s><s>A recent article revealed a strong association between access to (expensive) biologics and the country´s wealth <ref type="bibr" target="#b7">[8]</ref>.</s><s>Interestingly however, another review found that drug coverage for innovative and expensive drugs does not necessarily translate into its use; there were differences in use between countries with comparable reimbursement criteria, and also between regions within a country <ref type="bibr" target="#b8">[9]</ref>.</s><s>Differences in attitudes among clinicians likely contribute to differences in treatment choices <ref type="bibr" target="#b9">[10]</ref>.</s></p><p><s>To our knowledge, limited data exists about the differences in values that rheumatologists attach to various treatment characteristics beyond efficacy and safety.</s><s>Little is known about how rheumatologists assess economic consequences of a treatment choicedo they take into account relative CE considerations or primarily use absolute costs to make economic trade-offs?</s><s>Moreover, there is limited research on how rheumatologists consider patient´s preferences.</s></p><p><s>In this study, we aim to assess if rheumatologists across Europe are willing to trade-off treatment efficacy and safety for economic considerations and patients´ preferences.</s><s>Further, the study aims to determine different preference profiles of rheumatologists and whether preference profiles are associated with the country rheumatologists are located in.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>A discrete choice experiment (DCE) was designed to investigate relative preferences of rheumatologists when choosing drug treatments in RA.</s><s>In the DCE, rheumatologists were presented with a series of choices and asked in each to select the preferred drug treatment among two hypothetical treatment options (A or B).</s><s>The treatment options were described by a set of attributes, further specified by attribute levels.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selection of Attributes and Levels and Patient Profile</head><p><s>Selection of attributes and levels is fundamental in the design of a reliable DCE study <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>We followed a step wise approach.</s><s>First, potentially important attributes, attribute definitions and levels were identified from literature <ref type="bibr" target="#b10">[11,</ref><ref type="bibr">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref><ref type="bibr" target="#b15">[17]</ref><ref type="bibr" target="#b16">[18]</ref><ref type="bibr" target="#b17">[19]</ref><ref type="bibr" target="#b18">[20]</ref><ref type="bibr" target="#b19">[21]</ref><ref type="bibr" target="#b20">[22]</ref><ref type="bibr" target="#b21">[23]</ref>.</s><s>Second, an expert group (n=6) consisting of rheumatologists and experts in the field of economic evaluations, DCE and decision-making agreed on an initial list of attributes/definitions/levels.</s><s>Third, the proposed candidate attributes/definitions/levels were discussed with 8 rheumatologists from three countries to ensure they reflected clinical realities.</s></p><p><s>Five attributes were selected for the DCE: efficacy (status and improvement of disease activity score of 28 joints (DAS28), safety (risk of a serious adverse event (AE)), patient´ s preference (level of agreement with treatment choice), annual drug costs and CE (Incremental Cost-effectiveness Ratio (ICER) compared to usual care expressed as incremental cost of one quality adjusted life year (QALY) gain)).</s><s>For each attribute, three levels were agreed (figure <ref type="figure">1</ref>).</s></p><p><s>The patient profile (possibly influencing treatment choices) was selected to imply a clear need for change in the treatment and a decisional problem in terms of balancing previously agreed attributes.</s><s>The patient profile allowed for a switch to expensive (biological) medications in the majority of countries to ensure respondents do not feel intuitively restricted in their decision by local health care regulations.</s><s>The agreed profile described a patient with anti-citrulline antibody positive RA and moderate disease activity despite two conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs).</s><s>The full patient profile (online supplementary table <ref type="table" target="#tab_0">S1</ref>) has been approved by experts and rheumatologists</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental design</head><p><s>Based on the attributes and levels there are 243 (3 5 ) possible treatment combinations -too many to ask each rheumatologist to evaluate <ref type="bibr" target="#b22">[24]</ref>.</s><s>We reduce the number of choice sets using a Bayesian efficient experimental design (Ngene software <ref type="bibr">[25]</ref>).</s><s>A Bayesian design aims to maximize precision of estimated parameters for a given number of choice questions <ref type="bibr" target="#b23">[26]</ref> by incorporating a priori information about sign and value of parameters.</s><s>The a priori information was gained from a preliminary DCE with 10 rheumatologists.</s><s>Implausible or unrealistic treatment options were excluded from the design (e.g.</s><s>efficacy is low, costs are high, but the CE is best).</s><s>In addition three choice sets were included to test if respondents made sensible choices.</s><s>1. a dominance testa choice set with one treatment option that is clearly better the other; and 2. two repeated choiceschoice sets that repeat earlier choices to assess the stability of respondents´ choices.</s><s>A total of 17 choice sets were included in the questionnaire.</s><s>An example of a choice set is shown in figure <ref type="figure">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The questionnaire</head><p><s>The questionnaire consisted of two parts -1. the DCE task and 2. questions collecting socio-demographic data (e.g.</s><s>age, gender, work environment) to facilitate interpretation of the results.</s><s>The full questionnaire was piloted among rheumatologists (n=14) from two different countries to ensure that choice sets, attributes and levels were relevant, clear and plausible across countries.</s><s>Economic attributes were presented in local currencies <ref type="bibr">[27]</ref>.</s><s>An online survey was distributed by email through a national principle investigator (PI) per country.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Country selection</head><p><s>As attitudes of rheumatologists may be influenced by external factors like the country´s culture, wealth or health care environment, countries from all geographic regions in Europe were invited: Belgium (BE), France (FR); Germany (GE), Hungary (HU), Italy (IT), Netherlands (NL) Norway (NO), Portugal (PT), Romania (RO), Spain (SP), Sweden (SE) and United Kingdom (UK).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>A rheumatologists responses were considered for data analyses when at least 50% of choice sets were completed and they successfully passed the dominance test.</s><s>A three-step approach was used to analyse data.</s></p><p><s>First, a mixed logit (ML) model was used to assess the relative importance of attributes, using Nlogit, version 5 <ref type="bibr">[28]</ref>.</s><s>The following utility model was estimated:</s></p><formula xml:id="formula_0">Uij = β0 + (β1 + ɳ1i) Good response + (β2+ ɳ2i) Remission + (β3+ ɳ3i) Rare AE + (β4+ ɳ4i) Uncommon AE + (β5+ ɳ5i) Favoured preference + (β6+ ɳ6i) Disfavoured preference + (β7+ ɳ7i) Cost-effectiveness + (β8+ ɳ8i) Costs</formula><p><s>U represents the observable relative preference of rheumatologist (i) for a treatment choice (j) which can be defined as a sum of preference scores for attributes/levels.</s><s>β0 is the constant, β1-8 are the mean attribute utility weights (physician's preferences) for the respective attribute and ɳi represents the random parameter for rheumatologist i. Dummy coding was used to describe variables β1-6.</s><s>Reference categories for efficacy, safety and patient´s preference were moderate response, very rare adverse events and neutral patient attitude, respectively.</s><s>The signs of the β coefficients indicate whether the attribute has a negative or positive effect on the rheumatologists' preference.</s><s>A ML model allows model parameters to vary between respondents, which is reflected in the random parameter.</s><s>If the standard deviation (SD) of this random parameter is significantly different from zero, this is interpreted as evidence of significant preference variation for the attribute within the population <ref type="bibr" target="#b24">[29]</ref>.</s><s>Results were considered significant for p&lt;0.05.</s></p><p><s>The relative importance of attributes was calculated based on the range of the level coefficients per attribute.</s><s>using the method described by Malhotra and Birks <ref type="bibr" target="#b26">[30]</ref>.</s><s>More specifically, the relative importance weights were derived by dividing the range of the level coefficients for one attribute by the sum of ranges of coefficients of all attributes.</s></p><p><s>Second, to assess potential similarities, countries were grouped on the basis of their similarity in mean relative importance weights across the five attributes.</s><s>Hierarchical Ward´s linkage with a squared Euclidean distance measure was used (using STATA version <ref type="bibr">12 [31]</ref>).</s><s>To determine the optimal cluster number, a second clustering method (k-means) was applied and results were compared to hierarchical Ward´s linkage to verify if cluster structures were reproducible.</s><s>Introduction of additional clusters was stopped where both clustering methods provided different results.</s><s>Further we based the decision on numbers of clusters on the rule of thumb suggesting ~√(/2), with k describing the number of suggested clusters and the number of observations.</s><s>Third, a latent class model (LCM, using Nlogit) was used to determine preference profiles of all individual rheumatologists.</s><s>LCM can be used to identify the existence of and the number of classes in the population based on their treatment preferences.</s><s>The LCM can also be used to explore if covariates (such as clusters of countries) influence the probability to belong to a particular class.</s><s>Class membership is latent in that each respondent belongs to each class up to a modelled probability <ref type="bibr" target="#b27">[32]</ref>.</s><s>In order to determine the number of classes, we selected the model with the best fit based on the Akaike information criterion.</s><s>To further understand the role of country, previously developed country clusters were added as covariate to the latent class model in an additional step.</s><s>Statistically significant parameter estimates (p&lt;0.05)</s><s>indicate that the covariate (i.e. the dummy of country-cluster) contributes to the explanation of latent classes.</s><s>For example, if the parameter estimate for the covariate "country cluster" is positive and significant for a certain class, it indicates that rheumatologists from the countries that belong to the country cluster are more likely to belong to that particular class.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Respondent's socio-demographic characteristics</head><p><s>Overall 559 rheumatologists from 12 European countries were included in the analysis.</s><s>Mean age was 48.0 years and 49% of rheumatologists were females (table <ref type="table" target="#tab_0">1</ref>).</s><s>Test-retest reliability was in line with existing literature <ref type="bibr" target="#b24">[29]</ref> with 82.3% (re-test 1) and 80.8% (re-test 2) of respondents having chosen the same alternative in the test-retests.</s><s>Five respondents failed in the dominance test and were therefore excluded from the analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Attribute preferences when selecting a new treatment, overall and at a country-level</head><p><s>The main results of the MLmodel are summarized in table 2a (coefficients) and 2b (relative importance) for all countries and each country separately.</s><s>The detailed results overall and per country from ML models can be extracted from online supplementary table <ref type="table" target="#tab_4">S2</ref>.</s></p><p><s>Coefficients (table 2a) revealed, that in all countries good response and especially remission were significantly more desirable than moderate response (βremission&gt;βgood response).</s><s>When coefficients were significant, probability of a serious adverse event decreased preference for that given treatment option (βuncommon&lt;βrare).</s><s>The patient´s agreement with the treatment was universally associated with an increased preference and a stronger, negative impact on preference was seen when patients dislike treatments (|βdisagreement|&gt;|βagreement|).The contribution of patient´s disagreement with a treatment choice was significant in all countries.</s><s>The economic aspect also played an important role.</s><s>Higher economic burden was consistently associated with decreased preference.</s><s>CE was not significant in three countries (FR, IT, RO), medication costs however were significant in all countries.</s></p><p><s>When comparing contribution of different attributes across countries (table 2b), results revealed that efficacy dominated the treatment choice in all countries with comparatively low variations between countries (range 39-52%).</s><s>High variability was observed for the relative contribution of safety (range 1-20%) whereas patient´s preference played role in all countries (range 7-21%).</s><s>Similarly, absolute costs played a role in all countries (range10-24%) whereas contribution of CE varied importantly with several countries largely disregarding CE (range 4-21%).</s><s>In the majority of countries absolute costs were more important than relative CE considerations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cluster of countries according to the preference profile</head><p><s>Two clusters were identified (table 2).</s><s>In cluster 1 (BE, GE, HU, NL, NO, SE, SP, UK) all attributes, except safety, had a relevant contribution to treatments choice.</s><s>In cluster 2 including (FR, IT, PT RO), there was a higher emphasis on safety (range 18-20%) and lower emphasis on relative CE considerations (range 3-8 %).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Classes of individual rheumatologists according to the preference profile</head><p><s>Four classes of rheumatologists have been identified according to their preference profile (table <ref type="table" target="#tab_7">3</ref>).In all classes, efficacy (both levels) and patient´s disagreement with a treatment were significant determinants of treatment choice.</s><s>In class 1, rheumatologists accounted for both economic attributes (absolute costs and relative CE) but largely disregarded safety.</s><s>Overall, 43% of rheumatologists were estimated to belong to class 1. Rheumatologists belonging to one of the remaining classes 2-4 disregarded ICER.</s></p><p><s>Respondents of class 3 balanced safety and total medication costs, while those in class 2 and 4 accounted only for either safety (class 2) or total medication costs (class 4)</s></p><p><s>. The probabilities to belong to classes 2, 3 and 4 were estimated with 22.6%, 31.1% and 11.1% respectively.</s><s>Rheumatologists from country cluster 2 (FR, IT, PT RO) were significantly more likely to be located in classes 2, 3 and 4, with CE playing a minor role.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The study revealed that across countries rheumatologists are willing to trade-off efficacy against patients´ preferences and/or economic aspects in treatment choices.</s><s>43% of rheumatologists balanced all attributes, including CE when choosing a therapy, while for all other rheumatologists, CE did not play a substantial role.</s><s>Medication costs however remained relevant for 77% of clinicians.</s><s>Two groups of countries could be distinguished.</s><s>One group, which represented the majority of countries, was more likely to balance all treatment attributes including CE, while the other group placed little emphasis on CE.</s></p><p><s>In all countries, rheumatologists considered economic, indicating that rheumatologists support efficient use of limited health care resources.</s><s>However, latent class analyses showed that about half of individual rheumatologists are estimated to largely disregard the CE.</s><s>This can be explained by clinicians having limited access to CE data of relevant drugs or methodological complexities and weaknesses in existing data <ref type="bibr" target="#b28">[33,</ref><ref type="bibr">34]</ref>.</s><s>Given the importance of ICER, we need to ensure that trustful and comparable good quality data are provided to clinicians to support its use in clinical decision making.</s><s>In addition, the direct health care environment often rather supports economic trade-offs based on absolute costs <ref type="bibr" target="#b29">[35]</ref> even though CE data provide more valuable information on efficient treatment choices for society.</s><s>The present findings confirmed that in UK CE and more specifically ICER plays a more decisive role in reimbursement decisions compared to many other European countries <ref type="bibr" target="#b30">[36]</ref>.Of note, CE studies are frequently limited to selected countries although transferability of data across countries is not always possible, further limiting its use <ref type="bibr" target="#b28">[33]</ref>.</s></p><p><s>Patients´ preferences were taken into account by all rheumatologists, despite variations observed among individuals and between countries.</s><s>Cultural differences in the physician-patient relationship or the physician´s attitude may partly explain the differences.</s><s>A recent review e.g.</s><s>found that clinicians are more likely to support shared-decision making when their direct work environment supports the concept <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>Interestingly however, rheumatologists from all countries considered in particular patient´s disagreement, possibly to avoid poor drug adherence.</s><s>Although perception towards shared decision making can vary, this study for the first time revealed consensus among individuals and across countries on the importance of a patient´s disagreement, and is the first to address patient´s preferences in the context of other treatment attributes.</s><s>Some limitations have to be considered for interpretation of results.</s><s>First, the sample size was lower in some countries and differences in socio-demographics across countries were observed, thus selection bias and limitations in generalizability of results cannot be excluded.</s><s>Sub-group analyses of the results from NL (results not reported), revealed no significant differences in preferences for different sub-groups.</s></p><p><s>Further an efficient experimental design was developed to optimize response efficiency.</s><s>Second, pharmaceutical industry [37] or local health care regulations (in particular the reimbursement criteria) may influence the preferences.</s><s>However, most participating countries do not restrict access to expensive drugs for patients described in the DCE, therefore this type of effect is likely limited to countries with very strict criteria (UK, HU and RO).</s><s>Third, although the presented attributes were confirmed as most relevant for treatment decisions in RA and a strong methodology was used to select and defined attributes, it cannot be excluded that further attributes play a role in some countries.</s><s>Further research could contribute to a better understanding on other relevant factors across European countries.</s><s>Fourth, presenting two economic attributescosts and CE -in the DCE has it´s limitation as also absolute costs together with efficacy and safety provide insights into CE of a drug.</s><s>However, only including both economic attributes allowed to raise awareness on the fact that clinicians are still predominantly focused on costs.</s></p><p><s>Finally, this study provides only insight into stated preferences.</s><s>It remains unknown whether rheumatologists reach decisions in the same way in clinical practice as they state in the theoretical framework of the DCE.</s><s>Also, in clinical reality however decisional problems may exceed the complexity reflected in the study design.</s><s>Revealed preferences would be additionally informative, however design and execution of such a study would be very difficult.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Despite limitations, this study reveals that values rheumatologists attach to treatment characteristics vary importantly between countries and among individual rheumatologists. The complexity of today´s treatment</head><p><s>decisions justifies more research on behavior of prescribers, as the clinicians' attitude is one important factor contributing to quality and equality in healthcare.</s><s>We hope the current study will raise awareness on the importance of physicians' behaviors and open discussion on how clinicians are expected to trade-off various aspects of a treatment decision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>Overall, rheumatologists take efforts to balance multiple aspects of a treatment choice including the patient´s potential disagreement and the economic consequences.</s><s>However important differences in the assessment of economic aspects were observed between and within countries.</s><s>In most countries clinicians still focus on absolute costs while CE would provide more valuable information on the societal consequences of a decision.</s><s>Parameter estimates indicate that rheumatologists belonging to country cluster 2 (consisting of Romania, France, Portugal and Italy) compared to country cluster 1 (reference) are significantly more likely to be in classes 2, 3 or 4.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tables and Figures</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>000 EUR/year) -0.12*** -0.19*** -0.19*** -0.15*** -0.18*** -0.14*** -0.09*** -0.16*** -0.09*** -0.12*** -0.19*** -0.23*** -0.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 : Characteristics of rheumatologists for the total group and each country separately</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Gender</cell><cell>Age</cell><cell>Work environment</cell></row><row><cell></cell><cell></cell><cell>nfemale/noverall</cell><cell>years ± SD</cell><cell>nacademic/noverall</cell></row><row><cell></cell><cell></cell><cell>(% female)</cell><cell></cell><cell>(%) academic setting</cell></row><row><cell>Belgium</cell><cell>(n=33)</cell><cell>16/32 (53%)</cell><cell>41.4 ± 8.0</cell><cell>16/32 (53%)</cell></row><row><cell>France</cell><cell>(n=40)</cell><cell>21/38 (55%)</cell><cell>51.7 ± 10.6</cell><cell>2/38 (5%)</cell></row><row><cell>Germany</cell><cell>(n=44)</cell><cell>16/43 (37%)</cell><cell>49.3 ± 8.9</cell><cell>8/43 (19%)</cell></row><row><cell>Hungary</cell><cell>(n=71)</cell><cell>48/70 (69%)</cell><cell>50.6 ± 11.1</cell><cell>34/70 (49%)</cell></row><row><cell>Italy</cell><cell>(n=59)</cell><cell>20/57 (35%)</cell><cell>44.0 ± 11.4</cell><cell>31/57 (54%)</cell></row><row><cell>Netherlands</cell><cell>(n=63)</cell><cell>28/63 (44%)</cell><cell>48.9 ± 7.6</cell><cell>21/63 (33%)</cell></row><row><cell>Norway</cell><cell>(n=41)</cell><cell>22/39 (56%)</cell><cell>47.6 ± 10.2</cell><cell>17/39 (44%)</cell></row><row><cell>Portugal</cell><cell>(n=39)</cell><cell>19/36 (53%)</cell><cell>46.7 ± 12.8</cell><cell>11/36 (31%)</cell></row><row><cell>Romania</cell><cell>(n=42)</cell><cell>25/42 (59%)</cell><cell>43.3 ± 9.2</cell><cell>20/42 (48%)</cell></row><row><cell>Sweden</cell><cell>(n=24)</cell><cell>16/24 (67%)</cell><cell>50.5 ± 9.7</cell><cell>18/24 (75%)</cell></row><row><cell>Spain</cell><cell>(n=63)</cell><cell>31/62 (50%)</cell><cell>48.1 ± 8.3</cell><cell>54/62 (87%)</cell></row><row><cell cols="2">United Kingdom (n=40)</cell><cell>9/40 (23%)</cell><cell>53.5 ± 8.1</cell><cell>34/40 (85%)</cell></row><row><cell>All countries</cell><cell>(n=559)</cell><cell>267/546 (49%)</cell><cell>48.0 ± 10.1</cell><cell>266/546 (49 %)</cell></row></table><note><p><s>N= number of responses, SD= standard deviationFigure 1:</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Attributes and levels and example choice set of DCE experiment (a) Attributes and levels describing drug treatment options in DCE experiment</head><label></label><figDesc></figDesc><table><row><cell>ATTRIBUTES AND ATTRIBUTE</cell><cell>ATTRIBUTE LEVELS</cell><cell>LEVEL DESCRIPTIONS</cell></row><row><cell>DEFINITIONS</cell><cell></cell><cell></cell></row><row><cell>Efficacy</cell><cell>1. Good DAS28 response -</cell><cell>DAS28 improvement by 3.0 points</cell></row><row><cell>*Improvement and status of disease</cell><cell>remission achieved</cell><cell>Achievement of remission (DAS28&lt;2.6)</cell></row><row><cell>activity based on DAS28</cell><cell></cell><cell></cell></row><row><cell></cell><cell>2. Good DAS 28 response -low</cell><cell>DAS28 improvement by 2.0 points</cell></row><row><cell></cell><cell>disease activity achieved</cell><cell>Achievement of low disease activity</cell></row><row><cell></cell><cell></cell><cell>(2.6&lt;DAS28≤ 3.2)</cell></row><row><cell></cell><cell>3. Moderate DAS28 response</cell><cell>DAS28 improvement by 1.0 point</cell></row><row><cell></cell><cell></cell><cell>Low disease activity or remission cannot</cell></row><row><cell></cell><cell></cell><cell>be achieved (DAS28 remains &gt;3.2)</cell></row><row><cell>Safety</cell><cell>1. Very rare</cell><cell>5 out of 100,000 patients</cell></row><row><cell>Probability of a serious adverse</cell><cell>2. Rare</cell><cell>5 out of 10,000 patients</cell></row><row><cell>event</cell><cell>3. Uncommon</cell><cell>5 out of 1,000 patients</cell></row><row><cell>Patient´s Preference</cell><cell>1. Treatment favoured</cell><cell></cell></row><row><cell>patient expressed level of</cell><cell>2. Neutral</cell><cell></cell></row><row><cell>agreement with treatment choice</cell><cell>3. Treatment disfavoured</cell><cell></cell></row><row><cell>Cost-effectiveness</cell><cell>1. Favourable</cell><cell>15,000 €/QALY</cell></row><row><cell>** ICER, in costs per QALY gained</cell><cell>2. Moderate</cell><cell>30,000 €/QALY</cell></row><row><cell></cell><cell>3. Unfavourable</cell><cell>75,000 €/QALY</cell></row><row><cell>Overall medication costs</cell><cell>1. Low</cell><cell>800 EUR/year</cell></row><row><cell>Per year, in local currency</cell><cell>2. Medium</cell><cell>8,000 EUR/year</cell></row><row><cell></cell><cell>3. High</cell><cell>14,000 EUR//year</cell></row><row><cell>(b)</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Example choice set -repeated 17 times with varying attribute levels</head><label></label><figDesc></figDesc><table><row><cell>EXAMPLE CHOICE SET</cell><cell cols="2">TREATMENT A</cell><cell cols="2">TREATMENT B</cell></row><row><cell>Improvement of DAS28 disease</cell><cell cols="2">Good response -</cell><cell cols="2">Good response -</cell></row><row><cell>activity</cell><cell cols="2">Low disease activity achieved</cell><cell cols="2">remission achieved</cell></row><row><cell></cell><cell cols="2">DAS28 improved from 4.6 to 2.6</cell><cell cols="2">DAS28 improved from 4.6 to 1.6</cell></row><row><cell></cell><cell></cell><cell>SCJ improved from 5 to 2</cell><cell></cell><cell>SCJ improved from 5 to 1</cell></row><row><cell></cell><cell></cell><cell>TJC improved from 5 to 2</cell><cell></cell><cell>TJC improved from 5 to 1</cell></row><row><cell></cell><cell></cell><cell>ESR improved from 18 to 4</cell><cell></cell><cell>ESR improved from 18 to 2</cell></row><row><cell></cell><cell></cell><cell>PGA improved from 49 to 29</cell><cell></cell><cell>PGA improved from 49 to 19</cell></row><row><cell>Risk of serious adverse events</cell><cell cols="2">Rare -</cell><cell cols="2">Uncommon -</cell></row><row><cell></cell><cell cols="2">5 patients out of 10,000 patients</cell><cell cols="2">5 patients out of 1,000 patients</cell></row><row><cell>Patient´s preference</cell><cell cols="2">The patient disfavours treatment</cell><cell cols="2">The patient favours treatment</cell></row><row><cell>Cost-effectiveness</cell><cell cols="2">Unfavourable -</cell><cell cols="2">Moderate -</cell></row><row><cell></cell><cell cols="2">75,000 EUR/QALY</cell><cell cols="2">30,000 EUR/QALY</cell></row><row><cell>Medication costs</cell><cell cols="2">High -</cell><cell cols="2">High -</cell></row><row><cell></cell><cell cols="2">14,000 EUR/year</cell><cell cols="2">14,000 EUR/year</cell></row><row><cell>Which treatment would you choose</cell><cell></cell><cell>Treatment A</cell><cell></cell><cell>Treatment B</cell></row><row><cell>for the patient?</cell><cell></cell><cell></cell><cell></cell><cell>X</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>In the example choice set the respondent preferred treatment B over treatment A when choosing a drug treatment for a patient with moderate disease activity</head><label></label><figDesc><div><p><s>DCE=discrete choice experiment, DAS28=disease activity core 28; ICER =incremental cost effectiveness ratio, QALY=quality-adjusted life year * In the choice sets, also changes of the individual DAS28 components (tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR), patient global assessment of disease activity (PGA)) were presented  see figure1** ICER is expressed in costs (€) per QALY gained for the selected treatment compared to usual care</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 : Results from the Discrete Choice Experiment a) Results from the Random Parameters Logit Model</head><label>2</label><figDesc><div><p><s>(β coefficients per attribute level reflecting physician's preferences for the respective attribute)</s></p></div></figDesc><table><row><cell>Country/N</cell><cell>BE</cell><cell>NO</cell><cell>GE</cell><cell>SE</cell><cell>NL</cell><cell>UK</cell><cell>HU</cell><cell>SP</cell><cell>FR</cell><cell>IT</cell><cell>PT</cell><cell>RO</cell><cell>All countries</cell></row><row><cell>Treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Attribute/Level</cell><cell>33</cell><cell>41</cell><cell>44</cell><cell>24</cell><cell>63</cell><cell>40</cell><cell>71</cell><cell>63</cell><cell>40</cell><cell>59</cell><cell>39</cell><cell>42</cell><cell>559</cell></row><row><cell>Efficacy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Moderate response</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Reference level (efficacy)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Good response</cell><cell>2.08***</cell><cell>2.93***</cell><cell>2.93***</cell><cell>2.81***</cell><cell>2.40***</cell><cell>1.92***</cell><cell>2.31***</cell><cell>3.33***</cell><cell>2.49***</cell><cell>2.41***</cell><cell>3.40***</cell><cell>4.96***</cell><cell>2.30***</cell></row><row><cell>Remission</cell><cell>3.55***</cell><cell>4.32***</cell><cell>5.44***</cell><cell>5.05***</cell><cell>4.40***</cell><cell>3.47***</cell><cell>4.34***</cell><cell>5.35***</cell><cell>3.90***</cell><cell>4.66***</cell><cell>5.07***</cell><cell>8.86***</cell><cell>3.91***</cell></row><row><cell>Safety</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Very rare</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Reference level (safety)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rare</cell><cell>-0.37</cell><cell>-0.30</cell><cell>-0.65**</cell><cell>-0.82**</cell><cell>0.14</cell><cell>0.00</cell><cell>-0.41**</cell><cell>-0.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>12***</head><label></label><figDesc></figDesc><table><row><cell>Constant</cell><cell>0.14</cell><cell>-0.15</cell><cell>-0.40**</cell><cell>-0.30</cell><cell>-0.26**</cell><cell>-0.32**</cell><cell>-0.15</cell><cell>0.02</cell><cell>-0.16</cell><cell>-0.31**</cell><cell>-0.24</cell><cell>-0.57</cell><cell>-0.15***</cell></row><row><cell>McFadden Pseudo R-squared (R2).</cell><cell>0.61</cell><cell>0.65</cell><cell>0.66</cell><cell>0.67</cell><cell>0.46</cell><cell>0.63</cell><cell>0.63</cell><cell>0.65</cell><cell>0.58</cell><cell>0.63</cell><cell>0.64</cell><cell>0.63</cell><cell>0.39</cell></row><row><cell cols="11">BE=Belgium, FR=France, GE=Germany, HU=Hungary, IT=Italy, NL=Netherlands, NO=Norway, PT=Portugal, RO=Romania, SE=Sweden, SP=Spain, N= number of responses per country and overall,</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">*** significant at 1%, ** significant at 5%, * significant at 10%,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="8">All parameters were included as random parameters and assumed to be normally distributed. The estimation was conducted using 1000 Halton draws.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>b)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Contribution of each of the treatment attributes to the overall preference for a treatment choice</head><label></label><figDesc><div><p><s>(mean per country, in percent (%) of total explained variance) , FR=France, GE=Germany, HU=Hungary, IT=Italy, NL=Netherlands, NO=Norway, PT=Portugal, RO=Romania, SE=Sweden, SP=Spain, N= number of responses per country and overall, DAS28= Disease Activity Score in 28 joints, AE=Adverse Event, ICER=Incremental Cost-Effectiveness Ratio, n.a.=not applicable, R 2 =McFadden Pseudo R-squared</s></p></div></figDesc><table><row><cell>Country/N</cell><cell>BE</cell><cell>NO</cell><cell>GE</cell><cell>SE</cell><cell>NL</cell><cell>UK</cell><cell>HU</cell><cell>SP</cell><cell>FR</cell><cell>IT</cell><cell>PT</cell><cell>RO</cell><cell>All countries</cell></row><row><cell>Treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Attribute</cell><cell>33</cell><cell>41</cell><cell>44</cell><cell>24</cell><cell>63</cell><cell>40</cell><cell>71</cell><cell>63</cell><cell>40</cell><cell>59</cell><cell>39</cell><cell>42</cell><cell>559</cell></row><row><cell>Country Clusters</cell><cell></cell><cell></cell><cell></cell><cell cols="2">Country Cluster 1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Country Cluster 2</cell><cell></cell><cell></cell></row><row><cell>Efficacy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Improvement</cell><cell>44%</cell><cell>40%</cell><cell>42%</cell><cell>43%</cell><cell>44%</cell><cell>39%</cell><cell>46%</cell><cell>45%</cell><cell>43%</cell><cell>45%</cell><cell>39%</cell><cell>52%</cell><cell>44%</cell></row><row><cell>DAS28</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Safety</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Probability of a</cell><cell>10%</cell><cell>10%</cell><cell>9%</cell><cell>11%</cell><cell>1%</cell><cell>2%</cell><cell>12%</cell><cell>10%</cell><cell>20%</cell><cell>18%</cell><cell>19%</cell><cell>19%</cell><cell>12%</cell></row><row><cell>serious AE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Patient´s Preference</cell><cell>14%</cell><cell>14%</cell><cell>14%</cell><cell>19%</cell><cell>17%</cell><cell>19%</cell><cell>16%</cell><cell>18%</cell><cell>21%</cell><cell>14%</cell><cell>14%</cell><cell>7%</cell><cell>16%</cell></row><row><cell>Cost-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Effectiveness</cell><cell>9%</cell><cell>12%</cell><cell>14%</cell><cell>10%</cell><cell>14%</cell><cell>21%</cell><cell>14%</cell><cell>10%</cell><cell>3%</cell><cell>8%</cell><cell>8%</cell><cell>4%</cell><cell>10%</cell></row><row><cell>ICER, QALY/year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Medication costs</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>per year, in local</cell><cell>23%</cell><cell>24%</cell><cell>19%</cell><cell>17%</cell><cell>24%</cell><cell>19%</cell><cell>12%</cell><cell>17%</cell><cell>13%</cell><cell>15%</cell><cell>20%</cell><cell>18%</cell><cell>18%</cell></row><row><cell>currency</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Model fit, R 2</cell><cell>0.61</cell><cell>0.65</cell><cell>0.66</cell><cell>0.67</cell><cell>0.46</cell><cell>0.63</cell><cell>0.63</cell><cell>0.65</cell><cell>0.58</cell><cell>0.63</cell><cell>0.64</cell><cell>0.63</cell><cell>0.39</cell></row></table><note><p><s>BE=Belgium</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 : Results latent class model distinguished 4 classes of respondents.</head><label>3</label><figDesc><div><p><s>Average class probability = Probability that individual respondent chooses drug treatments according to respective responder types (all 559 responses from 12 countries included in the analysis) 2)</s></p></div></figDesc><table><row><cell>Latent class model</cell><cell>Latent class 1</cell><cell>Latent class 2</cell><cell>Latent class 3</cell><cell>Latent class 4</cell></row><row><cell>(Responder type)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>All attributes (except</cell><cell>Emphasis on efficacy,</cell><cell>All attributes except cost-</cell><cell>Emphasize on efficacy,</cell></row><row><cell></cell><cell>safety) balanced</cell><cell>safety and patient´s</cell><cell>effectiveness balanced</cell><cell>patient dislike and costs</cell></row><row><cell></cell><cell></cell><cell>preference, economic</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>aspects less relevant,</cell><cell></cell><cell></cell></row><row><cell>Average class</cell><cell>43.2 %</cell><cell>22.6%</cell><cell>23.1 %</cell><cell>11.1 %</cell></row><row><cell>probability 1)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Efficacy</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Moderate response</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell></row><row><cell>Good response</cell><cell>1.98***</cell><cell>3.65***</cell><cell>2.32***</cell><cell>1.74***</cell></row><row><cell>Remission</cell><cell>3.08***</cell><cell>6.39***</cell><cell>3.38***</cell><cell>3.85***</cell></row><row><cell>Safety</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Very rare</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell></row><row><cell>Rare</cell><cell>0.09</cell><cell>-1.38*</cell><cell>-0.96***</cell><cell>-0.44</cell></row><row><cell>Uncommon</cell><cell>-0.07</cell><cell>-2.71***</cell><cell>-2.45***</cell><cell>-0.58*</cell></row><row><cell>Patient´s preference</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>favours treatment</cell><cell>0.33***</cell><cell>2.35***</cell><cell>-0.37**</cell><cell>0.53</cell></row><row><cell>neutral</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell><cell>Reference level</cell></row><row><cell>disfavours treatment</cell><cell>-0.84***</cell><cell>1.53***</cell><cell>-1.34***</cell><cell>-3.17***</cell></row><row><cell>Cost-effectiveness</cell><cell>-0.29***</cell><cell>-0.28*</cell><cell>-0.03</cell><cell>-0.07</cell></row><row><cell>(10,000 EUR/QALY)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Overall medication</cell><cell>0.13**</cell><cell>-0.02</cell><cell>-0.11***</cell><cell>-0.09***</cell></row><row><cell>costs (1000 EUR/year)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Constant</cell><cell>0.02</cell><cell>-1.64***</cell><cell>-0.22**</cell><cell>-0.34</cell></row><row><cell>Class probability model</cell><cell>_____</cell><cell>1.41***</cell><cell>2.09***</cell><cell>1.16*</cell></row><row><cell>-cluster 2 2)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>*** significant at 1%, ** significant at 5%, * significant at 10%, 1)</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors would like to thank all participating rheumatologists for their contribution to the study and the following clinical rheumatologists for their support in development of study design and</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical approval information</head><p><s>The survey included clinical personnel (rheumatologists) only, ethical approval was not required for this type of study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author disclosure statement</head><p><s>Monika Hifinger contributed during an unpaid extended maternity leave (2013-2016) agreed with Hexal AG, Germany.</s><s>Related to the topic of this study, all other co-authors have no disclosures to declare.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding:</head><p><s>The study described in this manuscript was done without any type of funding.</s><s>Participating rheumatologists did not receive any financial compensation.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Physician attitudes toward shared decision making: A systematic review. Patient education and counseling</title>
		<author>
			<persName><forename type="first">S</forename><surname>Pollard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bansback</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bryan</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-09">2015 Sep</date>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1046" to="1057" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jobanputra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jowett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<editor>iii-iv, xi-xiii</editor>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">42</biblScope>
			<biblScope unit="page" from="1" to="229" />
			<date type="published" when="2006-11">2006 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The burden of rheumatoid arthritis and access to treatment: uptake of new therapies</title>
		<author>
			<persName><forename type="first">B</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kobelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smolen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Health Econ</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S61" to="86" />
			<date type="published" when="2008-01">2008 Jan</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country&apos;s wealth? Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Putrik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Kvien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sokka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uhlig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boonen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-11">2014 Nov</date>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="2010" to="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The impact of patient-centered care on outcomes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Donner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Mcwhinney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Weston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Fam Pract</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="796" to="804" />
			<date type="published" when="2000-09">2000 Sep</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-03">2014 Mar</date>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="492" to="509" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaujoux-Viala</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010-06">2010 Jun</date>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="964" to="975" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Inequities in access to biologic and synthetic DMARDs across 46 European countries. Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Putrik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ramiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Kvien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sokka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pavlova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Uhlig</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-01">2014 Jan</date>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="198" to="206" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cost effectiveness in practice and its effect on clinical outcomes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Jönssona</surname></persName>
		</author>
		<author>
			<persName><surname>Rs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wilking</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Cancer Policy</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Extent and causes of international variations in drug usage -A report for the Secretary of State for Health</title>
		<author>
			<persName><forename type="first">M</forename><surname>Richards</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ</title>
		<author>
			<persName><forename type="first">J</forename><surname>Coast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Al-Janabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Horrocks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Vosper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Swancutt</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012-06">2012 Jun</date>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="730" to="741" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Costeffectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Van Der Velde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ieraci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Witteman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bombardier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="issue">7436</biblScope>
			<biblScope unit="page" from="65" to="78" />
			<date type="published" when="2004-02-14">2004 Feb 14. 2011 Jan</date>
		</imprint>
	</monogr>
	<note>Bmj</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</title>
		<author>
			<persName><forename type="first">F</forename><surname>Augustovski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beratarrechea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Irazola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rubinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tesolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonzalez</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013-03">2013 Mar-Apr</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Analysis of physicians&apos; perspectives versus patients&apos; preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Muhlbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nubling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Health Econ</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="193" to="203" />
			<date type="published" when="2011-06">2011 Jun</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Evaluating patients&apos; preferences for multiple myeloma therapy, a Discrete-Choice-Experiment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Muhlbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lincke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nubling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychosoc Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Barton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="335" to="344" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Callegari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1375" to="1384" />
			<date type="published" when="2008-07">2008 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kievit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Kuper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van De Laar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Jansen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008-09">2008 Sep</date>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1229" to="1234" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Factors that influence rheumatologists&apos; decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kievit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Van Hulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Riel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fraenkel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="842" to="847" />
			<date type="published" when="2010-06">2010 Jun</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Malottki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsourapas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Uthman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Routh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1" to="278" />
			<date type="published" when="2011-03">2011 Mar</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schoels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010-06">2010 Jun</date>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="995" to="1003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis and rheumatism</title>
		<author>
			<persName><forename type="first">D</forename><surname>Aletaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Karonitsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bathon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bombardier</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008-10-15">2008 Oct 15</date>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1371" to="1377" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Discrete choice experiments in health economics: a review of the literature</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>De Bekker-Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gerard</surname></persName>
		</author>
		<ptr target="http://www.choice-metrics.com/" />
	</analytic>
	<monogr>
		<title level="j">Health Econ</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="145" to="172" />
			<date type="published" when="2012-02">2012 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</title>
		<author>
			<persName><forename type="first">Reed</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lancsar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kilambi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Muhlbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Regier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename></persName>
		</author>
		<ptr target="https://www.limdep.com/products/nlogit/" />
		<imprint>
			<date type="published" when="1928">2013 Jan-Feb. March 2014. 28</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="3" to="13" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Hiligsmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Dellaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Dirksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Der Weijden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goemaere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Reginster</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Patients&apos; preferences for osteoporosis drug treatment: a discrete-choice experiment</title>
	</analytic>
	<monogr>
		<title level="j">Arthritis research &amp; therapy</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">R36</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Marketing research: An applied approach. Pearson Education</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Nk Malhotra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">31. StataCorp. 2011. Stata Statistical Software: Release 12. College Station TSL</title>
				<imprint>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Men&apos;s preferences for prostate cancer screening: a discrete choice experiment</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>De Bekker-Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Donkers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Essink-Bot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Bangma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Steyerberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="533" to="541" />
			<date type="published" when="2013-02-19">2013 Feb 19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The costeffectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Innvar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lorenc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Woodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Joensuu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huoponen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Aaltonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Konttinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nordstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blom</surname></persName>
		</author>
		<idno>14:2. 34</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e0119683</biblScope>
			<date type="published" when="2014">2014. 2015</date>
		</imprint>
	</monogr>
	<note>PLoS One</note>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Barriers to using cost-effectiveness analysis in managed care decision making. The American journal of managed care</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Prosser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Koplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Weinstein</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000-02">2000 Feb</date>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="173" to="179" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Using threshold values for cost per qualityadjusted life-year gained in healthcare decisions. International journal of technology assessment in health care</title>
		<author>
			<persName><forename type="first">I</forename><surname>Cleemput</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Neyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Thiry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Laet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2011-01">2011 Jan</date>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="71" to="76" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
